Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

KEY TAKEAWAYS German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a ...

Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be ...